Navigation Links
BioMS Medical to present at BioCentury Conference
Date:3/24/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, March 24 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at the BioCentury "Future Leaders in the Biotech Industry" Conference in New York.

WHEN: Thursday March 27th at 2:00pm (Eastern Time)

WHERE: The Millennium Broadway Hotel & Conference Center, New York

About BioCentury "Future Leaders in the Biotech Industry" Conference

-------------------------------------------------------------------- This conference offers senior investment professionals an opportunity to review investment opportunities: companies making the transition from the private to public equity markets, as well as public plays positioned to move between tiers based on value or milestones. For more information visit: http://www.biocentury.com/BCApp/BioCenturyCommon/BCConferences.aspx?ss=1

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, MBP8298, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking st
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. BioMS Medical Announces 2007 Year End Results
2. BioMS Medical to present at BIO CEO & Investor Conference
3. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
4. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
5. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
6. BioMS Medical announces third quarter 2007 results
7. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
8. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
9. BioMS Medical to present at BioContact 2007
10. BioMS Medical announces its intention to renew a normal course issuer bid
11. SBT Acquisition Inc. Successfully Completes Tender Offer for Shares of Lifecore Biomedical, Inc.

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...rstCall/ -- BioSpecifics Technologies Corp. (Nasda... first-in-class collagenase-based products, today ...ter ended September 30, 2009. ,, "We were extr...DA,s Arthritis Advisory Committee unanimously reco...X(TM) for the treatment of Dupuytren,s disease, an...
(Date:11/6/2009)...-FirstCall/ -- ,, 3Q09 Corporate Highlights:...arketing Authorization to Astellas Pharma Europe L...iness activities Expanded management team to incl...ctor, Commercial Operations Appointed Bradford S....chairman , Upcoming 2009 Milestones: ,...
(Date:11/6/2009)...rowhead’s 2010 Personalized Medicine Partner...bruary 22-24, 2010 in Philadelphia, has been annou...ht key issues in forming partnerships and engage t... Minneapolis, MN (PRWEB) Nove...2010 Personalized Medicine Partnerships Conference...
(Date:11/5/2009)... -- DSM Pharmaceutical Products today announced th...ix, Saint Jean D,Illac, France, where DSM will be ...er for Galenix commercial products on a global bas...ness development opportunities co-marketing Galeni...h of Galenix in drug product development and clini...
Breaking Biology Technology:Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 6NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 3
...sive challenges and opportunities for micro and na...anufacturing of the fibres but in the control and ...workshop will focus on the many challenges of fibr...-of-the art surface chemical analysis, including S...damental effects of topography in SIMS and XPS, AF...
...Calif., May 14 VaxGen,Inc. (OTC Bulletin Board: V...guidance on its expected monthly cash expenditures...n on April 9, 2008. VaxGen expects that,its averag...kely to exceed,$1 million, made up of the followin...real estate and facility, estimated at 32% of m...
...dea Biosciences, Inc.,(Nasdaq: RDEA ) today annou...e Company,s lead mitogen-activated ERK kinase (MEK...W) 2008 in San Diego., The oral presentation det... 20, 2008 at 3:30 p.m. Pacific Time Abstract ...Inhibitor Ameliorates Murine Colitis Se...
Other Biology Technology:Micro and Nano Scale Characterization of Fibers 2Vaxgen Files 10-Q for First Quarter With SEC, Provides Future Burn Rate Guidance 2Vaxgen Files 10-Q for First Quarter With SEC, Provides Future Burn Rate Guidance 3Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at Digestive Disease Week 2008 2
(Date:11/6/2009)...Monell Center and the Chinese Academy of Sciences ...eting on Taste and Smell Research. Organized by Mo...ll be the first international meeting on taste and...f Executive Officer, American Association for the ...Science magazine, will open the meeting with a ple...
(Date:11/4/2009)...reluctant to officially endorse green tea as a can...about its protective effects, including results of...rch , a journal of the American Association for Ca...al cancer. , Vassiliki Papadimitrakopoulo, M.D....cic/Head and Neck Medical Oncology at the Universi...
(Date:11/4/2009)...ns out, hold the power to help militaries and muni...up toxic waste on test sites. , Compounds known ...k in World War II and have been used in military m... are often used to propel tank shells and act like...creased knowledge of their environmentally harmful...
Breaking Biology News(10 mins):Monell Center joins with CAS to host Beijing meeting on taste and smell research 2Does green tea prevent cancer? Evidence continues to brew, but questions remain 2Genomic research will enable greener cleanup of military explosive test sites 2Scientists use bed bugs own chemistry against them 47664 1Scientists use bed bugs own chemistry against them 47664 2Scientists use bed bugs own chemistry against them 47664 3Scientists use bed bugs own chemistry against them 47664 4Minnesota Healthcare Community to Build State of the Art Health Information Exchange 47660 1Minnesota Healthcare Community to Build State of the Art Health Information Exchange 47660 2New Program May Help Teens at High Risk for Depression 47656 1New Program May Help Teens at High Risk for Depression 47656 2New Program May Help Teens at High Risk for Depression 47656 3
...h team based at Massachusetts General Hospital (MG...ocess of RNA interference (RNAi), a powerful new r...nimals. They used the RNAi process itself to find ...echanism, which someday may help to fight human di...ce and is receiving early online release on the Sc...
... learn to imitate sounds that are not typical of t... of vocal learning in a non-primate terrestrial ma...urther supports the idea that vocal learning is im...ships among animals that separate and reunite over...ats. , Researchers from the Amboseli Trust for Ele...
...Inc. (Nasdaq: NGEN), developer of advanced diagnos....S. Patent No. 6,867,048, "Multiplexed Active Biol...e. The ,048 patent relates to a method of addressi... multiple rows and columns of a microarray. The pa... the voltage associated with each electrode in a l...
Other Biology News:Scientists identify genetic pathways essential to RNA interference 2Elephants imitate sounds as a form of social communication 2Nanogen Issued Patent for Electronic Microarray With Memory 2
...as been demonstrated that oxidative stress is invo...ase, and cancer. Oxidative stress is the condition... physiological antioxidants exist leading to the d...to oxidative stress is through several antioxidant...
...al Human Serum-Single Donor • Human serum is ... be negative by a test for Human Immunodeficiency ...mmunodeficiency Virus (Anti-HIV 1/2), Hepatitis C ...ce Antigen (HbsAg) and Non-reactive by a screening...
...ProteoSpin Detergent Clean-up Micro Kit provides a...al of SDS, Triton X-100 and other detergents from ...umn chromatography using Norgens patented protein ...of processing 2 50 g of either acidic or basic pro...
Customized Profile from Novascreen-a Caliper Life Sciences Company
Biology Products: